Table 1 Relationship between lncRNA-6195 expression and the clinical characteristics of HCC patients

From: A novel lncRNA, TCONS_00006195, represses hepatocellular carcinoma progression by inhibiting enzymatic activity of ENO1

  

LncRNA-6195 expression levels

P value

  

Low expression

High expression

All cases

 

23

24

 

Age (years)

    

 ≤55

 

18

17

 0.559

 >55

 

5

 7

 

Gender

    

 Male

 

22

23

 0.975

 Female

 

1

 1

 

HBV-DNA (copies/ml)

    

 ≤103

 

18

13

 0.081

 >103

 

5

 11

 

Tumor size (cm)

    

 ≤ 5

 

11

10

0.671

 > 5

 

12

 14

 

Tumors (n)

    

 Multiple

 

4

6

0.524

 Solitary

 

19

 18

 

Cirrhosis

    

 Yes

 

15

19

0.285 

 No

 

8

 5

 

AFP (ng/ml)

    

 ≤20

 

6

7

 0.813

 >20

 

17

 17

 

Edmondson grade

    

 I–II

 

16

23

 0.017*

 III–IV

 

7

 1

 

Vascular invasion

    

 Yes

 

7

11

 0.278

 No

 

16

 13

 

Capsular invasion

    

 Yes

 

12

8

 0.192

 No

 

11

 16

 
  1. The median expression level of lncRNA-6195 was used as the cutoff. “Low expression” group include 23 patients whose lncRNA-6195 expression was lower than the median. “High expression” group include 24 patients whose lncRNA-6195 expression was higher than the median. Pearson’s χ test and Fisher's exact test were used to analyze the correlation between lncRNA-6195 expression levels and clinical features. *P < 0 .05.
Back to article page